To review the role and benefit of immunotherapy in SCLC
To discuss the controversy in prophylactic brain radiation versus MRI follow up
Use of triplets in Frail and elderly population
To explore future trials with promising agents
Date: Thursday, November 12th, 2020 at 3:00 PM EDT / 12:00 PM PDT
Speaker: Dr. Quincy Chu
Chair: Dr. Barbara Melosky
This webinar has been made possible through sponsorship from AstraZeneca.
Dr. Quincy Chu has been a Medical Oncologist at the Cross Cancer Institute since April 2005 with medical oncology training in Canada and subsequent phase I/clinical research fellowship in novel anti-cancer drugs at the Institute for Drug Development in San Antonio, Texas. During which he was involved in a large number of novel anti-cancer agents, and had extra training in novel trial design and clinical pharmacology. Currently he is an Associate Professor in the Department of Oncology of University of Alberta. He continues his clinical and translational research in novel drug development, including targeted agents and immune-oncology agents, in thoracic oncology. He is the co-Lead and Lead for Phase I unit and the Thoracic Research Unit, respectively, at the Cross Cancer Institute.
Dr. Barbara Melosky, MD, FRCP(C), is a clinical professor of medicine at the University of British Columbia and a medical oncologist at the BC Cancer Center in Vancouver. She graduated from medical school at the University of Manitoba and completed a residency in internal medicine and a fellowship in oncology at the University of British Columbia. Dr. Melosky specializes in thoracic malignancies.
She is Head of the Lung Tumour Group in the province of British Columbia.
Dr. Melosky sits on the Executive Lung Site Committee for the Canadian Cancer Trials Group (CCTG). She has chaired the annual Canadian Lung Cancer Conference, attended by over 375 participants, for the last 20 years. She is proud to have started and built the British Columbia Lung Cancer Biobank, which is actively used for research for all interested.
She is published extensively and is considered a national and international expert on thoracic malignancies.
For more information, please send requests to Robyn Leonard at firstname.lastname@example.org.